Abstract
A series of colorectal carcinomas (n = 49) resected from patients with known clinical outcomes were analysed for E-cadherin expression using in situ hybridisation to measure mRNA. Patients surviving 5 years or longer (n = 31) exhibited significantly higher levels of E-cadherin mRNA than those surviving less than 5 years (n = 18, P = 0.003). These preliminary results from this small sample suggest that E-cadherin expression may be a useful prognostic marker in colorectal cancer patients.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Dorudi, S., Hanby, A., Poulsom, R. et al. Level of expression of E-cadherin mRNA in colorectal cancer correlates with clinical outcome. Br J Cancer 71, 614–616 (1995). https://doi.org/10.1038/bjc.1995.119
Issue Date:
DOI: https://doi.org/10.1038/bjc.1995.119
This article is cited by
-
Comprehensive analysis of CXCL14 uncovers its role during liver metastasis in colon cancer
BMC Gastroenterology (2023)
-
Tumour-suppressive function of SIRT4 in human colorectal cancer
British Journal of Cancer (2015)
-
Loss of E-cadherin promotes migration and invasion of cholangiocarcinoma cells and serves as a potential marker of metastasis
Tumor Biology (2014)
-
Tissue-based biomarkers predicting outcomes in metastatic colorectal cancer: a review
Clinical and Translational Oncology (2014)
-
Positive Expression of LSD1 and Negative Expression of E-cadherin Correlate with Metastasis and Poor Prognosis of Colon Cancer
Digestive Diseases and Sciences (2013)
